SCHEMBL16045979

SCHEMBL16045979

COc1ccc(OC(=O)O)c(C=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
ERN1 O75460 3/20 0.57
TRIM24 O15164 1/20 0.53
TYR P14679 1/20 0.53
TRIM33 Q9UPN9 1/20 0.53
JUN P05412 1/20 0.51
NFKB1 P19838 1/20 0.51
KDM4E B2RXH2 1/20 0.51
RAB9A P51151 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.48
CYP1A2 P05177 2/20 0.46
LMNA P02545 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16112011 0.88 ALDH1A1 (0.61) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL16046208 0.88 ALDH1A1 (0.71) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL4644522 0.87 ALDH1A1 (0.59) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL4644515 0.85 ALDH1A1 (0.57) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL1665643 0.85 ALDH1A1 (0.57) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL4645650 0.84 ALDH1A1 (0.56) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL4642070 0.83 KDM4E (0.54) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL1667861 0.83 ALDH1A1 (0.54) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL172939 0.82 ALDH1A1 (0.71) ALDH1A1ERN1TRIM24TYRTRIM33
SCHEMBL29392394 0.82 ALDH1A1 (0.71) ALDH1A1ERN1TRIM24TYRTRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920029-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-03-20 US disclosed
EP-2970183-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS Musc Foundation for Research Development (US) 2016-01-20 EP disclosed
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders MUSC Foundation for Research Development (10 pp.) 2015-08-06 US disclosed
US-9079853-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2015-07-14 US disclosed
WO-2014160143-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-10-02 WO disclosed
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders CLN6, AREG, HASPIN ALDH1A1 751/4885ERN1 1258/4885TRIM24 3939/4885
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS CLN6, AREG, HASPIN ALDH1A1 751/4885ERN1 1258/4885TRIM24 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.